Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cormedix Inc. is currently pursuing patent protection within the Biotechnology & Pharmaceuticals technology area. The portfolio includes 1 pending office action, which represents the current focus of the company's prosecution efforts. This activity level indicates a specific and targeted approach to intellectual property in the Biotechnology & Pharmaceuticals sector.
The prosecution is managed through 1 distinct art unit and involves 1 distinct examiner. This concentration suggests that the company's current applications are being evaluated within a narrow technical framework. For practitioners, the involvement of 1 distinct examiner means that the prosecution strategy is not diversified across multiple office perspectives.
HIRT, ERIN E is the busiest examiner for this portfolio, with a busiest examiner pending count of 1. This examiner is responsible for the 1 pending office action currently active. The success of the company's pending matters is therefore closely tied to the examination style and requirements of HIRT, ERIN E, who serves as the primary point of contact for these filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRT, ERIN E | 1 | 40.3% | +23.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18091504 | NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS | HIRT, ERIN E | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18091504 | NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS | HIRT, ERIN E | 34d |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18091504 | NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS | HIRT, ERIN E | 1616 | §103§112 | Final Rejection | 34d | Pending | Dec 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial